AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02067065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
Study NCT00554840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Study NCT00554840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Study NCT02492789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCSHR01210 injection
Description: Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study.
Study NCT03621111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-counseling
Description: After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
Study NCT03621111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient self-administered questionnaire
Description: The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
Study NCT03621111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pills counts
Description: At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
Study NCT02831894 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0% Hypnotic Medication Taper
Description: Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
Study NCT02831894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% Hypnotic Medication Taper
Description: Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
Study NCT02831894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Hypnotic Medication Taper
Description: Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
Study NCT01173874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Study NCT04465513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care + CARDIO
Description: Combination of dietary supplement with clinical care
Study NCT04465513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Best Standard of Care
Description: Combination of placebo with clinical care
Study NCT02948244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
Study NCT02948244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02815475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study NCT02815475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT02815475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric powder
Study NCT01488994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX326
Description: All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
Study NCT01719718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of hernia defect.
Description: Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
Study NCT03547934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused ElectroMagnetic system.
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
Study NCT01092962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
Study NCT01092962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1200mg/m²/jour in two divided doses during 18 months
Study NCT01918033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine 5 mg tablets
Study NCT04208048 — intervention group
Intervention type: DEVICE
Intervention: FLXfit 15TM device
Description: In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
Study NCT04385225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal follow-up
Description: Longitudinal hearing, vestibular and cognitive follow-up
Study NCT02345096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces cerevisiae
Study NCT01719718 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No closure of the hernia defect.
Description: Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
Study NCT00650715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands
Description: Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
Study NCT00650715 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Whole-body vibration exercise
Description: Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
Study NCT02345096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Saxagliptin
Description: Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, 500 mg, daily (42 months LT)
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Metformin
Description: Tablets, Oral, 0 mg, daily (42 months LT)
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT02013648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Study NCT00726076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebEase
Description: Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment
Study NCT00726076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebEase
Description: Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
Study NCT01485640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
Study NCT04299204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolitotomy
Description: Pediatric PCNL
Study NCT03232281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate PR 3-month
Description: 15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
Study NCT03232281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Acetate PR 1-month
Description: 3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
Study NCT01918033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to desloratadine 5 mg tablets
Study NCT01403246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide; Chlorambucil
Description: MTD of lenalidomide given in combination with chlorambucil
Study NCT01365507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Study NCT01918033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to desloratadine 5 mg tablets
Study NCT02311413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Study NCT02848014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing task
Study NCT02848014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing task
Study NCT00777647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drink
Description: One litre a day for six months.
Study NCT00777647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened soft drink
Description: One litre a day for six months.
Study NCT00777647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-skimmed milk
Description: One litre a day for six months
Study NCT00777647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: One litre a day for six months.
Study NCT02974296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: non invasive brain stimulation approach
Study NCT02974296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: non invasive brain stimulation approach
Study NCT03195114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodality Imaging and Biomarkers
Description: Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
Study NCT02327182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4666
Study NCT02105610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane, isoflurane, sevoflurane
Study NCT02105610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total intravenous anesthetics
Study NCT02505620 — intervention group
Intervention type: PROCEDURE
Intervention: Treatment of OSAS with CPAP mask
Description: Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
Study NCT02505620 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Treatment with multilevel operation
Description: Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
Study NCT01818076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin type A, Dose A applied to the lateral canthal area
Study NCT01227772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTSGC-A24
Description: OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
Study NCT02164747 — intervention group
Intervention type: DEVICE
Intervention: Residents of nursing homes with telemedicine after implementation of telemedicine
Study NCT04136392 — intervention group
Intervention type: DEVICE
Intervention: ABIOMED, Inc. hemodynamic support devices
Description: ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
Study NCT03809442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Ketamine
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
Study NCT03809442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Tramadol
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
Study NCT03809442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Midazolam
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
Study NCT03809442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
Study NCT03809442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexamethasone
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
Study NCT03809442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
Study NCT04382833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOT APPLICATION
Description: HOT APPLICATION
Study NCT04382833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MASSAGE
Study NCT01172847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir [Tamiflu]
Description: multiple oral doses
Study NCT01172847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir [Tamiflu]
Description: multiple oral doses
Study NCT01172847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rimantadine
Description: multiple oral doses
Study NCT01172847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimantadine
Description: multiple oral doses
Study NCT01702701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: montelukast 10mg po pill q day for 12 weeks
Study NCT01702701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: fluticasone 440mcg po q bid x 12 weeks
Study NCT03742609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ii) the reminder
Description: Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
Study NCT03742609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ii) written behavioural plan
Description: Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
Study NCT03742609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iv) all materials
Description: i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
Study NCT02408939 — intervention group
Intervention type: DRUG
Intervention: Stress-dose hydrocortisone
Description: Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
Study NCT03852303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: evaluate effect of ivermectin on frequency of seizures
Study NCT03852303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin
Description: evaluate effect of ivermectin on frequency of seizures
Study NCT03030573 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reconstruction of the bile duct with the round ligament
Description: In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
Study NCT03853447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic imaging
Description: MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
Study NCT00302042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling plus group diabetes prevention in community
Description: Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
Study NCT00302042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Counseling for pre-diabetes alone
Description: Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
Study NCT03669692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
Study NCT03669692 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
Study NCT02190227 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tumor RDA biopsy
Description: Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.